Myozyme Extensive Phase IV Program Includes Trial In Late-Onset Pompe
Executive Summary
Genzyme's Phase IV commitments for the Pompe disease therapy Myozyme (alglucosidase alfa) include randomized trials in late-onset Pompe disease patients
You may also be interested in...
Therapeutic Biologics Approvals Up In 2006, Overall BLA Approvals Steady
Overall 2006 biological license application approvals held steady from 2005 at 10 approvals, but the year saw a significant increase in approvals of therapeutic biologics
Therapeutic Biologics Approvals Up In 2006, Overall BLA Approvals Steady
Overall 2006 biological license application approvals held steady from 2005 at 10 approvals, but the year saw a significant increase in approvals of therapeutic biologics
Hectorol Will Drive Genzyme’s Renal Business; “Share Of Voice” To Jump
Genzyme expects its acquisition of Bone Care International will drive sales of both Hectorol (doxercalciferol) and Renagel (sevelamer) through the strength of joint promotions